Wolfe Research analyst Andy Chen upgraded Kymera Therapeutics to Outperform from Peer Perform with a $65 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Kymera Therapeutics TBA Spot Secondary priced at $44.75
- Morning Movers: Lowe’s moves lower after guidance cut
- Kymera Therapeutics $225M Spot Secondary priced at $44.55
- Kymera Therapeutics Announces Pricing of $225 Million Public Offering